With gene repair efficiency of up to 25% for some CYBB mutations and an on-target mutation rate of 75% at the endogenous CYBB locus, we believe that a donor template-free RGN approach has potential for personalized gene therapy of chronic granulomatous disease (CGD) and other monogenic blood disorders. This evidence concerns the gene CYBB and hematologic disorder.